Clonal Hematopoiesis-Associated Gene Mutations Affect Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation in AML Patients

Xiaoxuan Wei; Sai Huang; Zhenyang Gu; Jing Liu; Meng Li; Xiangshu Jin; Jian Bo; Fei Li; Yu Jing; Xiaoning Gao; Liping Dou; Daihong Liu; Chunji Gao

doi:10.12659/AOT.943688

02 July 2024 : Original article

Clonal Hematopoiesis-Associated Gene Mutations Affect Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation in AML Patients

Xiaoxuan Wei^12ABCDEF, Sai Huang^1ABF, Zhenyang Gu^1ADEF, Jing Liu^1ADEF, Meng Li^1AF, Xiangshu Jin^1AF, Jian Bo^1AF, Fei Li^1A, Yu Jing^1A, Xiaoning Gao^1A, Liping Dou^1AB, Daihong Liu^1A, Chunji Gao^1ADEF*

DOI: 10.12659/AOT.943688

Ann Transplant 2024; 29:e943688

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 6 Univariate and Multivariate analysis of the association of various clinical features with aGVHD in patients receiving allo-HSCT.

	Univariate analysis			Multivariate analysis
	OR	95% CI	P	OR	95% CI	P

Age (y)	0.984	0.960–1.008	0.179
Disease status at transplantation (non-CR vs CR)	0.841	0.335–2.110	0.712
NCCN^#
Intermediate vs favorable	0.820	0.391–1.717	0.598	0.795	0.359–1.762	0.572
Poor vs favorable	0.568	0.291–1.107	0.097	0.496	0.241–1.018	0.056
Donor type (matched vs haploidentical)	1.950	1.416–2.686	<0.001	3.760	2.005–7.049	<0.001
CH mutations (yes vs no)	1.566	0.878–2.794	0.129	1.497	0.803–2.792	0.205
Fungal (yes vs no)	0.316	0.077–1.302	0.111	0.229	0.052–1.012	0.052
, ≥
Mutated DNMT3A (yes vs no)^a	3.667	1.008–13.343	0.049	5.274	1.140–24.393	0.033
Mutated TET2 or ASXL1 (yes vs no)^c	2.139	0.540–8.480	0.279
Donor type (matched vs haploidentical)	1.584	0.598–4.196	0.355
Disease status at transplantation (non-CR vs CR)	0.283	0.030–2.676	0.271
EBV (yes vs no)	0.219	0.041–1.181	0.077	0.164	0.027–1.005	0.051
^a Patients with DNMT3A mutation but no TET2 or ASXL1 mutations; ^b patients without DTA mutations; ^c patients with TET2 or ASXL1 mutations but no DNMT3A mutation; ^# NCCN risk stratification is based on NCCN guidelines in 2021. OR – odds ratio; Allo-HSCT – allogeneic hematopoietic stem cell transplantation; NCCN – National Comprehensive Cancer Network; CH mutations – clonal hematopoiesis-associated mutation; CMV – cytomegalovirus; EBV – Epstein-Barr Virus.

Back to the Article

Clonal Hematopoiesis-Associated Gene Mutations Affect Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation in AML Patients

Your Privacy